Načítá se...
Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the liter...
Uloženo v:
| Vydáno v: | Case Rep Oncol Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800898/ https://ncbi.nlm.nih.gov/pubmed/31687241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3051945 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|